Qing Xu

Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy

A novel peptide-MHC-based T cell engager synergizes with tumor-targeted IL-12 for immunotherapy of solid tumors.

Conventional CD3-targeting bispecific T cell engagers (BiTEs) have shown limited efficacy in solid tumors, largely due to the highly immunosuppressive tumor microenvironment (TME) and systemic T cell activation-associated toxicity. To address this challenge, we developed a peptide-MHC class I-based T cell engager platf...

Single-cell-derived ferroptosis signature predicts prognosis and therapy response in esophageal squamous cell carcinoma

A single-cell-resolved ferroptosis gene signature with strong prognostic and therapeutic implications for ESCC is presented, showing that knockdown of CDCA3 lead to the downregulation of ferroptosis inhibitor-related genes and upregulation of ferroptosis-promoting genes, thereby enhancing the sensitivity to RSL3-induce...